Sonoma Biotherapeutics Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases by restoring balance to the immune system. The firm operates from South San Francisco and Seattle, reflecting a geographic focus in major biotech hubs in the United States. Its lead candidate, SBT-77-7101, is in Phase 1 studies to evaluate safety and proof of mechanism in patients with rheumatoid arthritis and hidradenitis suppurativa. The company positions itself within the biotechnology research industry, focusing on immune-regulatory therapies that aim to modify disease course. A strategic collaboration with Regeneron is part of its efforts to discover and develop novel regulatory T cell therapies. The organization was founded by leaders in regulatory T cell biology and cell therapy.